PYPD News and Press, PolyPid Ltd. From 07/28/21

PETAH TIKVA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its second quarter 20...

PETAH TIKVA, Israel, July 12, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a late-stage biopharma company focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, today announced that it has appointed leadi...

PETAH TIKVA, Israel, June 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, announced that Dikla Czaczkes Akselbrad, Executive Vi...

PETAH TIKVA, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that members of its executive management t...

FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX 100 for the Prevention of Surgical Site Infections in Colorectal Surgery. Enrollment in Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery Continues to ...

The FDA has indicated that a single Phase 3 pivotal study was adequate to support the approval of D-PLEX100, the lead candidate of PolyPid (PYPD), for the prevention of surgical site infections ((SSIs)) in colorectal surgery.The FDA’s written responses were in response to a T...

PolyPid's (PYPD) Q1 2021 Earnings Conference Call May 12, 2021, 08:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir Weisberg - Chief Executive Officer Dikla Czaczkes Akselbrad - Executive Vice President and Chief Financial Officer Noam Emanuel - Founder and Chief Scientific Off...

PolyPid (PYPD): Q1 GAAP EPS of -$0.47.As of March 31, 2021, the Company had cash and cash equivalents, short-term deposits and long-term deposits in the amount of $61.4 million, compared to $66.6 million at December 31, 2020. PolyPid (PYPD) continues to expect that this cash balance...

• Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery • Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks • Manufacturing Facility Now Fully Sc...

PETAH TIKVA, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its first quarter 20...